CML Advocates Network

Study title

OPTIC = Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

Scientific title

OPTIC (Optimising Ponatinib Treatment In CML) - A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses (EudraCT 2014-001617-12, NCT02467270, AP24534-14-203)

Indication and most important inclusion criteria

This study includes patients who:
- have chronic myeloid leukemia in chronic phase (CP-CML) and are resistant to at least two prior tyrosine kinase inhibitors (TKI)
- are at least 18 years old, have an Eastern Co-Operative Group (ECOG) status of 0-2, have given written informed consent and comply with scheduled visits and study procedures
- have fully recovered from the acute effects of prior cancer therapy before initiation of study drug
- have adequate kidney, liver and pancreas function
- have a negative pregnancy test, use a highly effective form of contraception from randomization through at least 4 months after the end of treatment (for female and male patients who are fertile)

Additional criteria apply.

Short description of intervention

To characterize the efficacy of ponatinib administered in three starting doses (45mg, 30mg, and 15mg daily) in patients with CP-CML who are resistant to at least two TKIs, as measured by major cytogenetic response (MCyR) by 12 months.

Type of study

Therapy optimization trials

Current status

Recruiting

Study sponsor

Ariad Pharmaceuticals (acquired by Takeda)

Scientific lead / contact

Takeda Study Registration Call Center 866-835-2233

Principal investigator

See site contact information

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Argentina

Buenos Aires, Argentina, 1221
Hospital Ramos Mejia (Site 826)
Contact: Claudio Merlo
Principal Investigator: Elena B Moiraghi, MD

Caba, Buenos Aires, C1114AAN
Fundaleu (Site 825)
Contact: Miguel Frau
Principal Investigator: Carolina Pavlovsky, M.D.

La Plata, Buenos Aires, B1900AXI
Hospital Italiano La Plata

Australia

New South Wales
St. Leonards, New South Wales, 2065
Royal North Shore Hospital (Site 941)
Contact: Vicki Katsioulas
Principal Investigator: Christopher K Arthur, MD

Adelaide, 5000
Royal Adelaide Hospital, Haematology Clinical Trials (Site 951)
Principal Investigator: Professor Timothy Peter Hughes

Canada

Ontario
Toronto, Ontario, M5G2M9
Princess Margaret Cancer Centre (Site 083)
Principal Investigator: Jeffrey Howard Lipton

Quebec
Montreal, Quebec, H3T IE2
Jewish General Hospital (Site 129)
Contact: Marie Pascale Guay
Principal Investigator: Sarit Assouline, MD

Saskatchewan
Regina, Saskatchewan, S4T 1A5
Pasqua Hospital (Site 227)
Principal Investigator: Haji Chalchal, MD

Chile

Providencia, Santiago, 7500922
Hospital del Salvador (Site 829)
Contact: Maria Gianna Capurro
Principal Investigator: Maria Soledad Undurraga Sutton, MD

Vina del Mar, Valparaiso, 254-0364
Centro de Investigaciones Clínicas Viña del Mar (Site 828)
Contact: Gina Castagneto
Principal Investigator: Christine Rojas Hopkins, MD

Czech Republic
Olomouc, 77520
Fakultni nemocnice Olomoue (Site 515)
Principal Investigator: prof. Karel Indrak, MD, PhD

Praha 2, 128 20
Ustav Hematologie a Krevni Transfuze Praha (UHKT) (Site 516)
Contact: Jana Vedrova
Principal Investigator: Hana Klamova

Denmark

Aarhus C, 8000
Haematologisk Afdeling, Arahus Universitehospital (Site 683)
Principal Investigator: Prof. Jesper Stentoft, M.D.

France

Angers Cedex 9, 44993 CHU Angers
Service Maladies du Sang (Site 685)
Principal Investigator: Dr. Martine Gardembas

Bordeaux, 33076
Centre de Lutte Contre le Cancer - Institut Bergonie (Site 772)
Principal Investigator: Dr. Gabriel Etienne

Lille, Nord, 59037 CEDEX Hopital Claude Huriez CHRU (Site 952)
Contact: Sylvie Brice
Principal Investigator: Valerie Coiteux, MD

Nantes Cedex, 44093
CHU Hotel-Dieu, Service d'Hematologie Clinique (Site 521)
Principal Investigator: Dr. Viviane Dubruille

Nice Cedex 3, 06202
Centre Hospitalier Universitaire de Nice Hopital l'Archet (Site 509)
Contact: Marie-Christine Rigualt
Principal Investigator: Laurence Legros

Poitiers, B.p. 577, 86021
CHRU de Poitiers, Department of Oncology-Hematology and Cell Therapy (Site 954)
Principal Investigator: Prof. Francois Guilhot

Toulouse Cedex 9, Midi-pyrenees, 31059
Institut Universitaire du Cancer de Toulouse Oncopole

Vandoeuvre-les-Nancy Cedex, 54511
University Teaching Hospital - CHU Brabois (Site 953)
Principal Investigator: Dr. Agnes-Paule Guerci-Bresler

Germany

Aachen, 52074
Universitätsklinikum Aachen, AOR (Site 513)
Contact: Sabrina Holst
Principal Investigator: Martina Crysandt, MD

Berlin, 13353
Universitätsmedizin Berlin - Charité (CVK) (Site 701)
Contact: Peggy Grill
Principal Investigator: Philipp Le Coutre, MD

Essen, 45147
Essen University Hospital (Site 686)
Contact: Ilona Vester
Principal Investigator: Jürgen Novotny, MD

Hamburg, 20246
University Cancer Center Hamburg (Site 524)
Hubertus Wald Tumorzentrum
Contact: Juliane Granzow
Principal Investigator: Philippe Schafhausen, MD

Jena, 07747
Universitätsklinikum Jena (Site 946)
Contact: Denise Mathes
Principal Investigator: Andreas Hochhaus, PhD, MD

Mannheim, 68169
University of Heidelberg (Site 947)
Contact: Regina Pleil-Losch
Principal Investigator: Susanne Saussele, MD

Rostock, 18057
Universitatsmedizin Rostock

Ulm, 89081
University Hospital of Ulm (Site 694)
Contact: Beate Böltau
Principal Investigator: Frank Stegelmann, MD

Hong Kong

Hong Kong, 852
Queen Mary Hospital

Italy

Catania, 95124
University Hospital Policlinico (Site 530)
Contact: Giovanna Pappalardo
Principal Investigator: Francesco Di Raimondo, MD

Genova, 16132
Azienda Ospedaliera Universitaria San Martino
V.O. Clinica Ematologica (Site 528)
Contact: Maria Attilia Grassi
Principal Investigator: Marco Gobbi

Monza, 20090
ASST San Gerardo Hospital (Site 355)
Contact: Dario Cerri
Principal Investigator: Carlo Gambacorti-Passerini, MD

Pesaro, Pesaro e Urbino, 61100
A.O. Ospedali Riuniti Marche Nord (Site 689)
Contact: Maurizio Nardelli
Principal Investigator: Giuseppe Visani, MD

Pescara, 65124
Pescara Civil Hospital (Site 688)
Contact: Giuseppina Di Florio
Principal Investigator: Paolo Di Bartolomeo, MD

Roma, 00161
University La Spienza (Site 511)
Contact: Enrica Arduini
Principal Investigator: Giuliana Alimena

Verona, 37134
Ospedale Borgo Roma - Verona (Site 687)
Contact: Giorgia Barbiero
Principal Investigator: Massimiliano Bonifacio, MD

Korea, Republic of

Seoul, Korea, Republic of, 137-701
The Catholic University of Korea Seoul
St. Mary's Hospital (Site 938)
Principal Investigator: Dong-Wook Kim, M.D., PhD

Poland

Gdansk, Pomorskie, Poland, 80-952
Uniwersyteckie Centrum Kliniczne

Krakow, 30-510
Malopolskie Medical Center (Site 546)
Contact: Marta Kowalowka
Principal Investigator: Tomasz Sacha, MD

Łódź, Poland, 93-510
Klinika Hematologii Uniwersytetu Medycznego w Łodzi (Site 550)
Contact: Magdalena Przybysz
Principal Investigator: Tadeusz Robak, MD

Warszawa, Poland, 02-776
Klinika Hematologii (Site 691)
Contact: Urszula Szustkiewicz
Principal Investigator: Krzysztof Warzocha, MD

Wrocław, Poland, 50-369
Independent Public Clinical Hospital No. 1 in Wroclaw (Site 547)
Contact: Mariusz Grajcar
Principal Investigator: Ewa Medras, MD

Portugal

Lisboa, 1090-023
Instituto Portugues de Oncologia de Lisboa (Site 545)
Contact: Ana Inacio
Principal Investigator: Antonio M Almeida, MD/PhD

Porto, 4200-319
Centro Hospitalar de S. João (Site 559)
Contact: Raquel Ribeiro
Principal Investigator: Manuel S Simões

Russian Federation

Chelyabinsk, 454076
Chelyabinsk Regional Clinical Hospital

Kemerovo, 650066
Kemerovo Regional Clinical Hospital (Site 455)
Contact: Ludmila Chervova
Principal Investigator: Marina Kosinova, MD

Moscow, 111123
GBUZ Moscow Clinical Scientific Center (Site 453)
Contact: Galina Dudina
Principal Investigator: Mikhail Y Byakhov, MD

Moscow, 125167
Russian Academy of Medical Science
Haematological Scientific Center (Site 452)
Contact: Nemchenko Irina, MD
Principal Investigator: Anna Turkina, MD

Rostov-na-Donu, Rostov, 344022
Rostov State Medical University

Saint Petersburg, 191024
FGU Russian Scientific Research Institute of Hematology and Transfusiology

Saint-Petersburg, 197341
Federal State Budgetary Institution V. A. Almazov
Federal North-West Medical (Site 454)
Contact: Irina Shakhomirova
Principal Investigator: Elza Lomaia, MD

Samara, 443099
Samara State Medical University

Saratov, Russian Federation, 355018
Saratov State Medical University

Singapore

Outram Road, Singapore, 169608
Singapore General Hospital (Site 939)
Principal Investigator: Dr. Charles Chuah Thuan Heng

Spain

Barcelona, Cataluna, 08036
Hospital Clinic, Service de Hematologia (Site 963)
Principal Investigator: Francisco Cervantes

Las Palmas de Gran Canaria, Islas Canarias, 35010
Hospital Universitario de Gran Canaria Dr Negrin (Site 692)
Contact: Mireya A Lopez
Principal Investigator: Maria Teresa Gomez Casares, MD

Madrid, 28006
Hospital Universitario de la Princesa
Hematology Service, 2a Planta (Site 555)
Principal Investigator: Juan Luis Steegmann Olmedillas

Madrid, 28034
Hospital Universitario Ramon y Cajal (Site 538)
Principal Investigator: Valentin Garcia Gutierrez
Hospital Clinico Universitario de Valencia (Site 964)

Malaga, Andalucia, 29010
Hospital Regional Universitario Carlos Haya (Site 698)
Principal Investigator: Antonio Jimenez Velasco

Valencia, Spain, 46010
Hospital Clinico Universitario de Valencia (Site 964)
Principal Investigator: Juan Carlos Hernandez Boluda

Sweden

Uppsala, SE-751 85
University Hospital Uppsala (Site 945)
Contact: Aime Mukenyuzi
Principal Investigator: Ulla Olsson-Stromberg, M.D., Ph.D.

Switzerland

Zurich, 8091
University Hospital Zurich (Site 562)
Contact: Isabell Pieper-Scholz
Principal Investigator: Stefan Balabanov, MD

Taiwan

Taipei, 100
National Taiwan University Hospital (Site 979)
Principal Investigator: Jih-Luh Tang, M.D., PhD.

United Kingdom

Glasgow, G12 0YN
NHS Greater Glasgow & Clyde
The Beatson West of Scotland Cancer Centre (Site 797)
Principal Investigator: Professor Tessa Holyoake

Liverpool, L7 8XP
The Royal Liverpool University Hospital (Site 969)
Principal Investigator: Professor Richard Clark

London, SE5 9RS
King's College Hospital NHS Foundation Trust (Site 693)
Principal Investigator: Dr. Hugues de Lavallade

London, W12 0NN
Imperial College Healthcare NHS Trust (Site 967)
Contact: Regina Storch
Principal Investigator: Jane F Apperley, MD

Nottingham, NG5 1PB
The Centre for Clinical Haematology
Notthingham University Hospitals NHS Trust (Site 968)
ontact: Maria Scott
Principal Investigator: Jennifer Byrne

Oxford, OX3 7LE
Churchill Hospital

United States

Georgia
Atlanta, Georgia, 30322
Emory University Hospital Winship Cancer Institute (Site 058)
Principal Investigator: Vamsi Kota, MD

Indiana
Indianapolis, Indiana, 46237
Indiana Blood and Marrow Transplantation Clinic (Site 138)
Principal Investigator: Luke Akard, MD

Maryland
Baltimore, Maryland, 21201
University of Maryland Medical Center (Site 040)
Principal Investigator: Maria Baer, MD

Michigan
Ann Arbor, Michigan, 48109
University of Michigan Health System (Site 011)
Principal Investigator: Moshe Talpaz, MD

Detroit, Michigan, 48201
Karmanos Cancer Institute (Site 034)
Principal Investigator: Charles Schiffer, MD

Minnesota
Minneapolis, Minnesota, 55455
University of Minnesota Medical School

Nebraska
Omaha, Nebraska, 68198-7680
University of Nebraska Medical Center (Site 235)
Principal Investigator: Lori Maness-Harris, MD

New Jersey
Hackensack, New Jersey, 07601
Hackensack University Medical Center (Site 128)
Principal Investigator: James McCloskey II

New York
New York, New York, 10065
Memorial Sloan Kettering Cancer Center (Site 078)
Contact: Gerald O'Neill
Principal Investigator: Michael Mauro, MD

New York, New York, 10065
Weill Medical College of Cornell University and New York Presbyterian Hospital (Site 006)
Contact: Rachael Alettie
Principal Investigator: Ellen Ritchie, MD

North Carolina
Durham, North Carolina, 27710
Duke University Medical Center (Site 003)
Contact: Cheryl M Maxey
Principal Investigator: Joseph Moore, MD

Ohio
Cleveland, Ohio, 44195
Cleveland Clinic Foundation (Site 004)
Principal Investigator: Dr. Sudipto Mukherjee

Oregon
Portland, Oregon, 97239
Oregon Health & Science University (Site 048)
Contact: Jeanne Liming
Principal Investigator: Michael Heinrich

Pennsylvania
Philadelphia, Pennsylvania, 19104
Abramson Cancer Center (Site 013)
Principal Investigator: Selena Luger, MD

Texas
Houston, Texas, 77030
MD Anderson Cancer Center (Site 005)
Principal Investigator: Jorge E. Cortes, MD

Utah
Salt Lake City, Utah, 84112
Huntsman Cancer Institute (Site 043)
Principal Investigator: Michael Deiningeri, MD

Study title

Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia (S1712)

Scientific title

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) (clinicaltrials.gov NCI-2017-02066)

Indication and most important inclusion criteria

This study includes patients who:
- are at least 18 years old
- have been diagnosed with chronic phase chronic myeloid leukemia (CML-CP) without any history of progression to accelerated or blast phase CML
- have been receiving treatment with dasatinib or nilotinib as first or second line therapy for a minimum of 6 months prior to registration
- have not received more than 2 tyrosine kinase inhibitors (TKIs) for treatment of CML (hydroxyurea prior to initiation of TKI is allowed)
- have been on their current TKI for a minimum of 6 months prior to randomization
- are expected to remain on the same TKI for the next 12 months
- have adequate liver and kidney function

Other criteria may apply. Please consult your doctor for further details.

Short description of intervention

This study assesses how well ruxolitinib phosphate and dasatinib or nilotinib work in treating patients with chronic myeloid leukemia. Ruxolitinib, dasatinib, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Type of study

Therapy optimization trial

Current status

Recruiting

Study sponsor

Southwest Oncology Group
National Cancer Institute (NCI)
Portland, Oregon, USA

Scientific lead / contact

Kendra L. Sweet, MD 

Principal investigator

Kendra L. Sweet, MD

Additional information

Study centers / principal investigators

United States

Southwest Oncology Group
National Cancer Institute (NCI)
Kendra L. Sweet, MD
Portland, Oregon 97239

Study title

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in Complete Cytogenic Remission (CCR) (ACTIW) [France]

Scientific title

Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design (ClinicalTrials.gov NCT02767063)

Indication and most important inclusion criteria

This study includes patients who:
- are at least 18 years old
- have Philadelphia chromosome positive (Ph+) and BCR-ABL1+ chronic myeloid leukemia in chronic phase (CP-CML)
- have been treated imatinib, nilotinib, dasatinib, bosutinib or ponatinib for more than 2 years overall
- have not switched between tyrosine kinase inhibitors within the last 3 months
- have achieved complete cytogenetic response (CCR) (BCR-ABL less than or equal 1% on the International Scale)
- have an Eastern Co-Operative Group (ECOG) status of 0-2
- have adequate liver and kidney function

Short description of intervention

The purpose of this study is to evaluate whether combination of a tyrosine kinase inhibitor (TKI) with another study drug can help achieve deep response (MR4.5).

Patients will receive either a TKI alone (imatinib, nilotinib, dasatinib, bosutinib or ponatinib at the same daily dose and schedule as during the last 3 months before inclusion in the study) or a TKI (imatinib, nilotinib, dasatinib, bosutinib or ponatinib at the same daily dose and schedule as during the last 3 months before inclusion in the study) in combination with another drug.

The first arm (TKI alone versus TKI + combination with pioglitazone) has been completed.

Additional treatment groups with other combinations are planned and include:
- a TKI in combination with avelumab
- a TKI in combination with pegylated interferon
- a TKI in combination with arsenic trioxide
- a TKI in combination with Homoharringtonine-
- a TKI in combination with anti-PD-L1 antibody

Type of study

Therapy optimization trial

Current status

Recruiting

Study sponsor

Hôpitaux de Versailles, Hôpital Mignot, France

Scientific lead / contact

Pr Philippe Rousselot
Centre Hospitalier de Versailles
France

Principal investigator

Pr Philippe Rousselot
Centre Hospitalier de Versailles
France

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

France

Angers, 49033
Service de Médecine D
CHU d'Angers
Dr Martine Gardembas

Bobigny, 93000
Service Hématologie
Hôp Avicenne
Dr Thorsten Braun

Bordeaux, 33076
Institut Bergonié
Dr Gabriel Etienne

Creteil,, 94010
Service Hématologie Clinique et Thérapie Cellulaire
CHU Henri Mondor
Dr Lydia Roy

Le Chesnay, 78157
Centre Hospitalier de Versailles
Hôpital André Mignot
Service de Médecine B Hématologie-Oncologie
Pr Philippe Rousselot (Coordinating Investigator)

Lille, 59037
Service des Maladies du Sang
Hôpital Claude Huriez
Dr Valérie Coiteux

Lyon, 69374
Service d'Hématologie
Hôpital Edouard Herriot
Dr Franck Nicolini

Marseilles, 13273
Service Hématologie
Institut Paoli Calmette
Dr Aude Charbonnier

Nantes, 44035
Service d'Hémato-Cancérologie
CHU Hôtel-Dieu
Dr Viviane Dubruille

Nimes, 30029
Service de Hématologie Oncologie
CHU Caremeau
Eric Jourdan

Orleans, 45100
Service d'Onco-Hématologie
Hôpital La Source
Dr Omar Benbrahim

Paris,75010
Centre D'investigations INSERM CIC9504
Hôpital St Louis
Dr Delphine Rea

Paris, 75571
Service de Hématologie Oncologie
CHU St Antoine
Dr Simona Lapusan

Poitiers, 86021
Département d'Hématologie et Oncologie et Inserm CIC 1402
CHU de Poitiers
Dr Emilie Cayssials

Pringy, 74370
Service d'Hématologie
Centre Hospitalier Annecy Genevois
Dr Pascale Cony.Makhoul

Rennes, 35033
Service Hématologie
CHU de Rennes
Dr Martine Escoffre-Barbe

Tours, 37000
Service Hémato-Oncologie
CHU de Tours
Dr Caroline Dartigeas

Study title

DasaHIT = Dasatinib Holiday for Improved Tolerability

Scientific title

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naive disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (2nd line) (EudraCT 2015-003502-16)

Indication and most important inclusion criteria

This study includes patients aged 18 years and above who have been newly diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemie (CML) in any phase or who have failed treatment or are intolerant to previous treatment with other tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, bosutinib, ponatinib). To be included patients must also have a score of at least 2 on the ECOG performance scale assessing the quality of life of cancer patients.

Patients with Ph-negative CML or socalled variant translocations, who are BCR-ABL-positive, are also considered eligible for inclusion.

Short description of intervention

This study will investigate whether treatment with dasatinib over two years is equally effective when dasatinib is not given on weekends (treatment pause) compared to daily administration of dasatinib without treatment pauses.

Type of study

First-line trial, trial after therapy failure or intolerance, therapy optimization trial

Current status

recruiting

Study sponsor

Friedrich-Schiller-Universität Jena, Germany, with financial support from Bristol-Myers Squibb

Scientific lead / contact

Prof. A. Hochhaus
Klinik und Poliklinik für Innere Medizin II
Universitätsklinikum Jena
Germany

Principal investigator

Prof. A. Hochhaus
Klinik und Poliklinik für Innere Medizin II
Universitätsklinikum Jena
Germany

Additional information

Short protocol

Study centers / principal investigators

Germany

Study title

ASC4MORE (CABL001E2201) = A Phase II Study of Asciminib in Combination With Imatinib for Patients with CML-CP without Deep Molecular Response

Scientific title

A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response (EudraCT 2018-001594-24, ClinicalTrials.gov NCT03578367)

Indication and most important inclusion criteria

Male or female patients 18 years and older with Philadelphia chromosome-positive CML in chronic phase who previously received first line treatment with imatinib. Patients can be considered for inclusion in the study if they have BCR-ABL results of more than 0.1% and up to 1% on the international scale (IS) at the screening examination and did not reach deep molecular response (MR4 or better) at any time during prior imatinib treatment. To be eligible for inclusion, patients must have acceptable laboratory values at screeing, electrolytes within normal limits, and adequate end-organ function.

Short description of intervention

This is a study of the efficacy and safety of asciminib in addition to imatinib compared to continued imatinib or compared to nilotinib in pre-treated CML-CP patients without a deep level of molecular response on imatinib.

Type of study

Therapy optimization trial

Current status

recruiting

Study sponsor

Novartis Pharmaceuticals

Scientific lead / contact

Novartis Pharmaceuticals

Principal investigator

Novartis Pharmaceuticals

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health 

Study centers / principal investigators

Australia

New South Wales
Novartis Investigative Site
Darlinghurst, 2010

South Australia
Novartis Investigative Site
Adelaide, 5000

Victoria
Novartis Investigative Site
Melbourne, 3000

Austria

Novartis Investigative Site
Graz, 8036

Novartis Investigative Site
Vienna, 1140

Canada

Novartis Investigative Site
Montreal, H1T 2M4

Chile

Novartis Investigative Site
Temuco, Araucania, 4810469

Novartis Investigative Site
Vina del Mar, Valparaiso, 2540364

Czech Republic

Novartis Investigative Site
Brno - Bohunice, 639 01


France

Novartis Investigative Site
Bordeaux, 33076

Germany

Novartis Investigative Site
Berlin, 13353

Novartis Investigative Site
Dresden; 01307

Novartis Investigative Site
Mannheim, 68305

Hong Kong

Novartis Investigative Site
Hong Kong

Italy

Novartis Investigative Site
Bologna, 40138

Novartis Investigative Site
Milano, 20162

Japan

Novartis Investigative Site
Shinagawa ku, Tokyo, 141 8625

Korea, Republic of

Novartis Investigative Site
Seoul, Seocho Gu, 06591

Novartis Investigative Site
Seoul, 03080

Poland

Novartis Investigative Site
Krakow, 31 531

Novartis Investigative Site
Warszawa, 02 776

Novartis Investigative Site
Wroclaw, 50 367

Portugal

Novartis Investigative Site
Lisboa, 1099 023

Novartis Investigative Site
Porto, 4200-072

Russian Federation

Novartis Investigative Site
Moscow, 125167

Novartis Investigative Site
Moscow, 115284

Novartis Investigative Site
Saint Petersburg, 191024

Novartis Investigative Site
Saint Petersburg, 197341

Spain

Novartis Investigative Site
Sevilla, 41009

Novartis Investigative Site
Las Palmas de Gran Canaria, 35010

Novartis Investigative Site
Madrid, 28034

Novartis Investigative Site
Valencia, 46026

Taiwan

Novartis Investigative Site
Changhua, 50006

Novartis Investigative Site
Taipei, 10002

Novartis Investigative Site
Taoyuan, 33305

United Kingdom

Novartis Investigative Site
London, W12 0HS

Novartis Investigative Site
Oxford, OX3 7LJ

Novartis Investigative Site
Wirral, Merseyside, CH63 4JY

USA

Illinois
University of Chicago
Chicago, 60637

Maryland
Sidney Kimmel Comprehensive Cancer Center
Baltimore, 21205

Saint Agnes Healthcare Cancer Institute
Baltimore, 21229

New York
SUNY- Stony Brook Medical Oncology Hematology/Oncology
Stony Brook, 11794-8174

Texas
University of Texas MD Anderson Cancer Center
Houston, 77030